Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of BridgeBio Pharma, Inc.. A complete text table follows the diagram.
Product revenue dominates the quarter, with licensing and royalties adding distinct biotech monetization paths.
Swipe to explore
Labels and displayed flow values are reported filing values or exact disclosed subtotals.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| BridgeBio Pharma revenue | 1 | $195M | $194.5M reported quarterly revenue |
| Net product revenue | 2 | $181M | 93% of total revenue |
| License and services revenue | 2 | $4.4M | Reported revenue |
| Royalty revenue | 2 | $9.5M | Reported revenue |
| From | To | Value |
|---|---|---|
| BridgeBio Pharma revenue | Net product revenue | $181M |
| BridgeBio Pharma revenue | License and services revenue | $4.4M |
| BridgeBio Pharma revenue | Royalty revenue | $9.5M |